Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Presymptomatic identification of disorders to allow for early initiation of treatment and consequent improvement in the long-term prognosis of affected patients
The conditions identifiable by amino acid and acylcarnitine analysis are detected by supplemental newborn screening using tandem mass spectrometry (MS/MS) as described here.
Analyte (assay platform) | ACMG Recommended Conditions | Additional Conditions/Treatment Detectable by MS/MS | |
Core Condition | Secondary Targets | ||
Amino Acids (MS/MS) | |||
Phe | PKU | BS HPA REG | TPN |
Leu/Ile, Val | MSUD |
| TPN |
Met | HCY | Met | TPN, nonspecific liver disease |
Cit, Arg, ASA | ASA CIT | ARG CIT-II |
|
Tyr | TYR-I | TYR-II TYR-III | Nonspecific liver disease |
GUAC |
|
| GAMT |
Acylcarnitines (MS/MS) | |||
C0 | CUD |
| Maternal CUD, maternal GA-I, maternal MCAD |
C3 | CblA, Cbl B MUT PA | Cbl C, Cbl D |
|
C4 |
| IBDH SCAD | FIGLU |
C5 | IVA | SBCAD | Antibiotics containing pivalic acid |
C5-OH | BKT HMG MCC MCD | MGA-I MHBD | Maternal MCC, biotinidase deficiency |
C8 | MCAD1 | GA-II1 MCKAT1 M/SCHAD1 |
|
C3-DC |
| MAL |
|
C10:2 |
| DR |
|
C5-DC | GA-I |
|
|
C14:1, C16, C18:1 | VLCAD | CACT CPT-I2 CPT-II |
|
C16-OH | LCHAD2 TFP2 |
|
|
m/z 225<399<473 |
|
| Dextrose infusion |
m/z 342 (C8:1) |
|
| Artifact often observed in premature neonates |
m/z 470 (C16:1OH) |
|
| Cefotaxime metabolite |
Succinylacetone | TYR-I |
|
|
Panel includes all disorders recommended by the American College of Medical Genetics detectable by Tandem Mass Spectrometry.(MS/MS)(1)
See Informative Markers for Supplemental Newborn Screening at Mayo Clinic in Special Instructions.
The following algorithms are available in Special Instructions:
Flow Injection Analysis-Tandem Mass Spectrometry (MS/MS)